Boston has never needed to be Silicon Valley.
That is becoming especially clear in artificial intelligence. While much of the AI conversation has centered on giant language models, chatbots, and consumer apps, Boston is building something different. Many of the most interesting AI companies in the region are applying intelligence to harder problems: drug discovery, biology, robotics, cybersecurity, engineering, weather, insurance, healthcare, construction, defense, and scientific research.
That difference matters.
Boston has a combination that few technology regions can copy. MIT sits next to a dense network of laboratories, hospitals, universities, biotechnology companies, robotics teams, defense contractors, financial firms, and venture investors. MIT alone says roughly 200 active companies headquartered in Massachusetts are based on MIT-licensed technologies. The university describes the Cambridge-Boston region as a major environment for building science and technology companies across fields including health, manufacturing, robotics, semiconductors, photonics, energy, defense, and biotechnology.
The state is also putting more infrastructure behind this shift. Massachusetts launched the Massachusetts AI Hub to connect research, startups, government, industry, and workforce development. In August 2026, MassVentures separately announced $4.5 million in grants for 26 Massachusetts startups working across AI, robotics, life sciences, quantum computing, energy, and other advanced technologies.
The result is an AI market that looks unusually physical.
Boston AI does not stop when an answer appears on a screen. Increasingly, the software designs a protein, helps investigate a cyberattack, controls a robot, predicts breast cancer risk, translates mission-critical code, helps manufacture a house, models the weather, designs a biological system, or coordinates a scientific experiment.
That is the central finding from our analysis of 25 Boston-area AI startups to watch in 2026.
This is not a ranking from number one to number 25. A cybersecurity company cannot be meaningfully ranked against an AI biology lab or an autonomous ship company using one simple score. Instead, we selected companies that help show where the Boston AI economy appears to be going next.
The Short Version: Boston Is Building AI That Has to Work in the Real World
Our biggest finding is simple: Boston’s strongest AI advantage may be where software meets difficult real-world systems.
We classified the 25 companies in this report into five broad groups. Seven work primarily in health and life sciences, seven in enterprise and workflow software, six in physical or deep technology, four in scientific AI, and one in creative AI.
Chart 1: Sector Mix Across the 25 Companies
| Sector | Companies | Share of List |
|---|---|---|
| Health and life sciences | 7 | 28% |
| Enterprise and workflow AI | 7 | 28% |
| Physical AI and deep tech | 6 | 24% |
| Scientific AI | 4 | 16% |
| Creative AI | 1 | 4% |
| Total | 25 | 100% |
Health and enterprise software may tie for the largest number of companies, but that does not tell the whole story. Scientific AI and physical AI together account for another 40% of our list.
In other words, nearly half of the companies we selected are applying AI to scientific or physical systems rather than conventional office software.
That feels very Boston.
Our Original Research: What the Funding Data Says
Funding is not a perfect measure of startup quality. A company can raise a huge round and fail, while a smaller company can create an important new market.
Still, financing gives us one useful signal: where investors are willing to place large bets.
For this article, BostonBizScene created a dataset from publicly disclosed financing announcements for the companies on our list. We used the most recent publicly disclosed venture equity round with an amount that we could verify. When a round was described as “more than” a figure, we used the stated figure as a minimum rather than trying to estimate the missing amount.
Two very early companies, Dipole Labs and Rindler, did not have a comparable disclosed financing amount in the public information we reviewed, so we excluded them from the funding calculations rather than guessing.
That left 23 companies.
The Result: At Least $2.45 Billion in Latest-Round Capital
The most recent disclosed rounds for those 23 companies total at least $2.45 billion.
That is not the lifetime funding raised by these companies. It is also not the total amount invested in Boston AI during 2026.
It is a deliberately narrower measure: one most recent publicly disclosed round per company.
The median latest round in our dataset is approximately $56.1 million, while the mean is roughly $106.7 million. The large difference between the median and mean shows how much a handful of enormous financings pull the total upward.
Chart 2: Latest Disclosed Round Capital by Sector
| Sector | Capital Represented | Share of Known-Round Pool |
|---|---|---|
| Physical AI and deep tech | ~$725M | 29.5% |
| Health and life sciences | ~$543.5M | 22.1% |
| Scientific AI | ~$496M | 20.2% |
| Creative AI | $400M+ | 16.3%+ |
| Enterprise and workflow AI | ~$289.9M | 11.8% |
| Total | At least $2.45B | 100% |
The physical-AI figure reflects disclosed rounds from companies including Walden Robotics, Code Metal, Tomorrow.io, Blue Water Autonomy, and Reframe Systems.
Health and life sciences include Beacon Biosignals, Clairity, Somite.ai, AI Proteins, Videa, Asimov, and Dyno Therapeutics.
Scientific AI includes Lila Sciences, Physical Superintelligence, Osmo, and Axiomatic AI.
Suno alone represents at least $400 million through its June 2026 Series D.
Enterprise and workflow AI includes the known rounds of 7AI, Maven AGI, Day AI, OpenHands, EnFi, and Gradient AI. Rindler is counted in the sector’s company total but excluded from its financing total because we did not find a comparable disclosed round amount.
Finding #1: Big Capital Is Flowing Into Boston’s Hardest Problems
The five largest recent rounds in our dataset are Suno at $400 million or more, Lila Sciences at $350 million, Walden Robotics at $300 million, Tomorrow.io at $210 million, and Asimov’s $175 million Series B.
Together, those five rounds represent roughly 58.5% of the known latest-round capital in our dataset.
What is more interesting than the dollar figure is what these companies actually do.
One generates music. One is trying to automate parts of scientific discovery. One is developing general-purpose robotics. Another operates an AI-driven weather platform supported by its own satellite infrastructure. The fifth builds computational systems for engineering biology.
This is a very different mix from an AI ecosystem built mostly around office productivity apps.
Finding #2: 2026 Has Already Produced a Large Share of the Capital Signal
Eleven of the 23 companies with known round data had their most recent disclosed financing in 2026.
Those rounds represent about $1.35 billion, or roughly 55% of the $2.45 billion latest-round pool.
Chart 3: Year of Most Recent Disclosed Round
| Latest Round Year | Capital in Our Dataset | Approx. Share |
|---|---|---|
| 2026 | $1.353B | 55.1% |
| 2025 | $770.3M | 31.4% |
| 2024 | $56.1M | 2.3% |
| 2023 | $175M | 7.1% |
| 2021 | $100M | 4.1% |
Again, this should not be read as Boston AI venture investment by year. We are simply looking at the year of the latest known financing for each company on our list.
The point is that the underlying startup set is not stale. A large part of the financial activity behind these companies happened during the last 21 months.
Finding #3: Boston’s AI Economy Is Splitting Into Two Layers
One layer consists of software companies that can deploy quickly: cybersecurity agents, CRMs, coding agents, lending systems, insurance software, and customer-service automation.
The other layer requires much more infrastructure. It includes laboratories, robots, satellites, factories, biological experiments, autonomous ships, healthcare data, optical hardware, and physical-world engineering.
Boston appears unusually capable of producing both at the same time.
That may prove to be one of its biggest advantages.
How We Chose the 25 Boston AI Startups
We began with public startup databases, accelerator lists, local ecosystem sources, company announcements, and recent financing news. We then checked company websites and recent reporting to confirm that each business remains active and has a meaningful connection to Greater Boston.
For this report, Greater Boston includes Boston, Cambridge, Somerville, Watertown, and nearby innovation centers where companies participate directly in the Boston technology ecosystem.
We required AI to be central to the company’s technology or business model. Simply adding an AI assistant to an existing software product was not enough.
We also checked location more carefully than many automated startup lists do.
That matters because startup geography changes quickly. OpenEvidence, for example, is still found on some Boston and Cambridge startup lists, but reporting from the Boston Globe says the company shifted its headquarters from Cambridge to Miami in summer 2025, and current company information lists Miami as its headquarters. We therefore did not count it as a current Boston-headquartered company.
The cutoff for this research is September 22, 2026.
25 Boston AI Startups to Watch in 2026
Scientific and Research AI
1. Lila Sciences
Lila Sciences may be one of the clearest examples of what makes the Boston AI ecosystem different.
Instead of building software that simply helps researchers search documents or summarize papers, Lila is working toward AI systems that can participate in the scientific process itself. Its platform is designed to connect AI with automated laboratories so software can form hypotheses, design experiments, run them, examine results, and continue learning.
The company announced a $350 million Series A in October 2025, bringing its disclosed seed and Series A financing to $550 million. Lila was founded in 2023 and has continued to announce scientific programs and partnerships through 2026.
Why Lila Matters
The important idea here is not simply “AI for science.”
It is the attempt to close the loop between digital intelligence and physical experiments. Most AI systems learn from information that already exists. A system connected to a laboratory can potentially create new data by deciding what experiment should happen next.
That could change the economics of R&D.
For Boston, the opportunity is enormous because the region already has deep talent in biology, chemistry, materials, healthcare, engineering, and computation.
What to Watch
Watch whether Lila can show repeated scientific discoveries that would have been slower or more expensive under conventional laboratory workflows. The bigger long-term question is whether AI-run science becomes an infrastructure category rather than simply another software category.
2. Physical Superintelligence
Physical Superintelligence, or PSI, is another sign that Boston AI is moving beyond language.
The Cambridge company announced a $58 million seed round in September 2026, led by Breakthrough Energy Ventures. PSI describes itself as an AI-native physics laboratory working on systems that can understand and design complex physical systems.
The team is already more than a simple two-founder research project. Company information describes a group of more than 25 people working across AI, physics, engineering, and related fields.
Why PSI Matters
Language models became powerful because the internet provided a huge training set of human language.
Physics is harder.
Much of the information needed to understand machines, energy systems, materials, and physical infrastructure does not exist as neat internet text. It comes from equations, simulations, sensors, engineering data, experiments, and physical measurements.
That creates an opportunity for companies designed specifically around physical intelligence.
What to Watch
Boston business leaders should watch which industries PSI targets first. Energy, industrial systems, advanced computing infrastructure, aerospace, and engineering are all areas where even small improvements in design can produce large economic value.
3. Osmo
Osmo is trying to teach machines something that AI has historically struggled to understand: smell.
The company was spun out of Google Brain in 2022. Osmo says it raised a $60 million Series A and a $70 million Series B in 2026, taking disclosed funding to roughly $130 million. It has also grown to more than 100 employees across its operations.
Its goal is sometimes described as “olfactory intelligence.” In simple terms, Osmo wants machines to understand the relationship between molecules and odor.
Why Osmo Matters
Smell sounds like a narrow market until you consider how many industries depend on molecules.
Fragrance, food, consumer products, agriculture, disease detection, environmental monitoring, manufacturing, and chemical safety can all involve smell or volatile compounds.
A machine that can reliably map molecular structure to human sensory experience could become useful infrastructure across several large industries.
What to Watch
The most important signal will be commercial use.
A fascinating model is not enough. Osmo becomes much more important if companies begin using its technology to shorten product-development cycles, identify molecules that humans struggle to discover, or create entirely new classes of sensory products.
4. Axiomatic AI
Axiomatic AI sits at the intersection of artificial intelligence, mathematics, physics, and engineering.
The Cambridge company raised an $18 million seed round in 2026. Its stated approach combines techniques such as machine learning, formal reasoning, and physics-based modeling, with a focus on producing answers that scientists and engineers can check rather than blindly trust.
That last point matters.
In engineering, a confident wrong answer can be far more expensive than no answer.
Why Axiomatic Matters
Generative AI’s biggest weakness in high-stakes technical work is reliability.
An engineer does not only need a plausible answer. The engineer needs to know why the answer works, what assumptions were used, and whether the result obeys physical and mathematical rules.
Axiomatic is attacking that problem directly.
What to Watch
Watch whether verifiable AI becomes a separate enterprise market.
If engineering teams decide that conventional language models are too difficult to trust for important calculations, companies built around proof, checking, constraints, and physical correctness could have a major opening.
Physical AI, Robotics and Deep Technology
5. Walden Robotics
Walden Robotics arrived in 2026 with one of the largest startup launches in Boston’s recent technology history.
The Cambridge company announced a $300 million seed financing in July at a reported $1.1 billion valuation. Toyota and Deviation led the round, with other participants including companies or investment groups connected to NVIDIA, Boeing, Samsung, and Prologis.
Walden is developing general-purpose robots for environments such as manufacturing and logistics.
Why Walden Matters
Robotics is entering a new phase.
Traditional industrial robots perform fixed tasks in structured environments. The bigger AI opportunity is to build machines that can adapt to more variable environments, learn more tasks, and require less custom engineering each time they are deployed.
Boston is well positioned for this market because it has decades of robotics talent.
What to Watch
The number that matters will eventually be deployments, not demonstrations.
A robot doing a clever task in a controlled video is interesting. A fleet running thousands of hours inside factories while producing measurable labor, safety, quality, or throughput improvements is a business.
Watch for those production metrics.
6. Code Metal
Code Metal is building AI for a problem that is invisible to most consumers but extremely important to large engineering organizations.
The Boston company uses AI and automated verification to help translate and modernize low-level software across different chips, devices, and computing architectures. Code Metal announced a $125 million Series B in February 2026. Customers and partners disclosed publicly have included organizations in defense, aerospace, semiconductors, and automotive technology.
The basic problem is simple: important software often needs to move from one type of computer system to another without breaking.
Doing that manually can take large engineering teams.
Why Code Metal Matters
AI code generation gets most of the attention when it writes a new web application.
Code Metal is going after a harder category where mistakes can have much larger consequences. Defense systems, vehicles, chips, embedded devices, and industrial machines cannot treat software translation as a casual experiment.
That creates a stronger barrier to entry.
What to Watch
Watch whether verified AI-generated code becomes accepted inside regulated and safety-sensitive industries.
If that happens, Code Metal could benefit from a very large pool of old software that companies need to modernize.
7. Tomorrow.io
Tomorrow.io is no longer simply a weather-app startup.
The Boston company is building an AI-native weather intelligence platform supported by its own satellite infrastructure. In May 2026, Tomorrow.io said it had expanded its Series F financing to $210 million.
Its customers use weather data to make operational decisions rather than merely deciding whether to carry an umbrella.
Airlines, logistics networks, governments, infrastructure companies, sports organizations, and other businesses can lose large amounts of money when weather changes faster than their systems can react.
Why Tomorrow.io Matters
This is a good example of Boston’s full-stack AI model.
The company combines physical infrastructure in space, proprietary data, forecasting systems, machine learning, and enterprise software.
That is much harder to copy than an application built entirely on another company’s AI API.
What to Watch
The most important question is whether proprietary sensing data becomes a durable AI advantage.
As foundation models become easier to access, unique data may become more important. Tomorrow.io is creating part of that data itself.
8. Blue Water Autonomy
Blue Water Autonomy is developing unmanned ships for naval applications.
The Boston company announced a $50 million Series A in August 2025, bringing its disclosed funding at that point to $64 million. Its plans include building full-sized autonomous vessels designed for long-range missions.
This puts the company inside one of the most important trends in defense technology: shifting more work from expensive, crewed platforms toward autonomous systems.
Why Blue Water Matters
The economics of autonomy look very different when a machine is a ship rather than a software agent.
Hardware cost matters. Energy matters. Reliability matters. Communications matter. Salt water matters. Maintenance matters.
Building autonomous systems that survive the physical world requires much more than a good AI model.
That technical difficulty is precisely why Boston may have an advantage.
What to Watch
Watch for actual sea trials, manufacturing capacity, military contracts, and deployment timelines.
Defense technology startups increasingly have to prove that they can move beyond prototypes and build hardware at useful scale.
9. Reframe Systems
Reframe Systems is applying robotics and what it calls physical AI to one of America’s least automated industries: homebuilding.
In August 2026, the company announced $40 million in additional venture-backed equity financing. Reframe operates a network of small automated factories designed to manufacture building components closer to where homes are needed.
Its Billerica FAB1 facility is designed to support hundreds of units annually. Reframe said in its funding announcement that it had already completed ten homes and expected to deliver another 114 units during the following year.
Why Reframe Matters
Construction has resisted software-driven productivity gains for decades because every building project is partly a physical coordination problem.
Reframe’s bet is that software, robotics, standardized processes, and local microfactories can turn more of homebuilding into a repeatable manufacturing system.
That is a much bigger idea than simply creating AI software for contractors.
What to Watch
Watch the real economics per completed home.
Production speed, factory utilization, labor hours, material waste, defect rates, and final project cost will tell us far more than the sophistication of the AI.
10. Dipole Labs
Dipole Labs is one of the youngest companies in this report.
The Boston startup joined Y Combinator’s Summer 2026 batch and is working on optical networking technology for AI computing clusters. The founders are former Harvard researchers, and the company describes its focus around photonic infrastructure for AI and advanced computing.
The company is early enough that public commercial data remains limited.
That is exactly why it is worth watching now.
Why Dipole Matters
The AI infrastructure problem is becoming larger than chips.
Thousands of accelerators inside AI clusters need to communicate with each other quickly and efficiently. Networking performance, power use, switching, and data movement can become major bottlenecks.
Optical systems could become increasingly important as AI computing clusters grow.
What to Watch
Dipole belongs in the “technical progress first” category.
Watch prototypes, customer tests, bandwidth and energy performance, manufacturing partnerships, and whether the technology can operate reliably at data-center scale.
Health and Life Sciences AI
11. Beacon Biosignals
Beacon Biosignals is building AI around brain data.
The Boston company works with EEG signals and other neurological information, giving pharmaceutical and healthcare organizations tools for measuring brain activity more effectively. Its Series B was expanded to more than $97 million in April 2026, taking cumulative financing above $132 million.
Beacon has also built hardware and software designed to make EEG data easier to capture outside traditional specialist settings.
Why Beacon Matters
Neurological disease is extremely difficult to measure.
Many clinical assessments depend on symptoms, questionnaires, limited tests, or short observations in controlled environments. Better continuous or scalable brain measurements could improve clinical trials and eventually care.
AI becomes valuable here because the raw signals are too complex for simple manual interpretation.
What to Watch
The critical test is clinical usefulness.
Watch whether Beacon’s measurements help pharmaceutical companies run faster trials, select patients more accurately, measure treatment effects, or reduce the number of failed development decisions.
12. Clairity
Clairity is using AI to identify health risk from medical images before obvious disease appears.
The Boston company announced a $43 million Series B in November 2025 to commercialize its breast-health platform. Its technology received FDA De Novo authorization for an AI system designed to estimate a woman’s five-year breast cancer risk from a mammogram.
That moves AI imaging beyond the familiar question, “Is something suspicious visible right now?”
The bigger question becomes, “What does today’s image tell us about future risk?”
Why Clairity Matters
Healthcare becomes much more valuable when it moves earlier.
Finding disease is useful. Helping identify which people may need closer screening or preventive action before disease is visible could be even more powerful.
That creates an opportunity for AI to turn routine medical images into richer sources of predictive data.
What to Watch
Clairity’s next challenge is adoption.
FDA authorization solves only one part of healthcare commercialization. Hospitals still need workflow integration, physician trust, reimbursement paths, strong evidence, and a clear reason to change established screening practices.
13. Somite.ai
Somite.ai is trying to use AI to improve the production of human cells.
The Boston company announced more than $47 million in Series A financing in May 2025. Its DeltaStem platform combines AI with biological data to model how cells develop and to create better recipes for producing specific cell types.
Later in 2025, AMD Ventures made a strategic investment as Somite continued building the computational infrastructure behind its platform.
Why Somite Matters
Cell therapy has an important manufacturing problem.
Knowing that a particular cell type could help treat a disease is not enough. Researchers must produce those cells reliably, consistently, and at a useful cost.
AI could help search through the enormous number of biological conditions and signals involved.
What to Watch
Watch for evidence that Somite can convert model predictions into repeatable biological manufacturing results.
The strongest proof will come from therapies, partners, or production processes that become meaningfully cheaper, faster, or more reliable because of the platform.
14. AI Proteins
AI Proteins uses artificial intelligence to design new miniproteins.
The Boston company announced a $41.5 million Series A in November 2025. Its platform focuses on de novo protein design, meaning it attempts to create useful proteins rather than only searching nature for ones that already exist.
This is part of a much larger transformation in biotechnology.
AI increasingly allows researchers to treat biological molecules more like things that can be designed.
Why AI Proteins Matters
Protein drugs can be powerful, but conventional discovery is expensive and slow.
If AI can design smaller proteins with specific shapes and functions, researchers may be able to explore drug candidates faster and target biological mechanisms that are difficult to reach with older approaches.
Boston’s biotechnology ecosystem gives companies like AI Proteins immediate access to scientific talent and potential partners.
What to Watch
The next important signal is not simply better model performance.
It is experimental validation.
Watch how many designed proteins survive the move from computer prediction into laboratory tests and, eventually, clinical development.
15. Videa
Videa is one of Boston’s stronger examples of vertical AI already moving into everyday professional work.
The company builds AI for dental imaging and dental practices. It announced a $40 million Series B in January 2025, and in 2026 said its products were being used by tens of thousands of clinicians and by many of North America’s largest dental service organizations.
Its dental AI software has also gone through FDA review, an important hurdle in clinical technology.
Why Videa Matters
Dentistry is a useful lesson for every vertical-AI founder.
The biggest opportunity is often not to build a generic AI system and search for users afterward. It is to understand one profession deeply enough to fit into its daily decisions, data, regulations, and economics.
Videa has spent years doing that in dental care.
What to Watch
Watch how far the company expands beyond image interpretation.
The larger opportunity is to connect clinical intelligence with patient communication, treatment planning, practice operations, and revenue workflows without weakening clinical trust.
16. Asimov
Asimov is building a platform for designing biological systems and manufacturing advanced medicines.
The Boston company announced a $175 million Series B as part of a larger $200 million funding announcement in January 2023. Its platform combines biological engineering with software and computational design, and the company has continued releasing new systems through 2026, including its RNA Edge platform.
Asimov came from research connected to MIT and Boston University and remains headquartered in Boston.
Why Asimov Matters
AI in biology does not stop at discovering a drug.
A medicine also has to be manufactured.
That is especially difficult for gene therapy, cell therapy, RNA products, and other advanced biological products. Small changes in biological systems can affect yield, quality, safety, and cost.
Asimov is targeting this engineering layer.
What to Watch
Watch adoption of its design systems by drug developers and manufacturers.
The strongest long-term position may belong to platforms that become part of the infrastructure used repeatedly across many therapies rather than betting everything on a single drug.
17. Dyno Therapeutics
Dyno Therapeutics uses machine learning to design better viral vectors for gene therapies.
Founded in 2018, the company later established its headquarters in Watertown. Dyno raised a $100 million Series A in 2021, and its more recent commercial progress provides the stronger reason to watch it in 2026.
In April 2026, Astellas exercised an option on a second AI-designed capsid from Dyno, triggering a $15 million payment plus potential future milestones and royalties.
Why Dyno Matters
Gene therapy needs delivery vehicles that can reach the right tissues while avoiding unwanted effects.
That creates a giant design problem.
Instead of testing a limited number of naturally occurring viral capsids, machine learning can help explore a far larger design space.
Dyno was early to that idea.
What to Watch
The most important validation now comes from partners.
Licensing events, clinical development, regulatory progress, and real human data will show whether AI-designed biological delivery systems can outperform older methods in practice.
Enterprise, Cybersecurity and Workflow AI
18. 7AI
7AI is one of the fastest-growing cybersecurity startups in Boston’s current AI wave.
The company announced a $130 million Series A in December 2025, bringing disclosed funding to $166 million. Its product uses autonomous AI agents to investigate security alerts and handle parts of the work normally performed by security analysts.
By May 2026, 7AI said its platform had processed more than seven million investigations. It also announced plans to add 100 AI-related jobs in Boston.
Why 7AI Matters
Security teams have suffered from alert overload for years.
Adding another dashboard does not solve the problem.
The agent model changes the value proposition because the software attempts to complete parts of the investigation rather than simply displaying more information for a human to process.
What to Watch
The best metric is not the number of alerts touched by AI.
It is the number of investigations resolved correctly with less human effort, while avoiding dangerous misses.
For security buyers, accuracy and auditability matter more than automation theater.
19. Maven AGI
Maven AGI is developing enterprise AI for customer service and customer experience.
The Boston company announced a $50 million Series B in June 2025, bringing total disclosed funding at that point to $78 million.
Its larger idea is that customer support software should move beyond answering a question and toward solving the customer’s actual problem.
That distinction is becoming important across the agentic-AI market.
Why Maven Matters
A chatbot can produce a polite answer while failing to complete the task.
Businesses do not get much value from that.
The next generation of service AI needs access to workflows, customer information, billing systems, order systems, and internal knowledge so it can complete more of a service request.
What to Watch
Measure resolution rather than conversation volume.
If a company can show that its agents complete a growing share of customer problems without lowering satisfaction or creating risk, that is a much more meaningful signal than the number of AI chats.
20. Day AI
Day AI is rebuilding customer relationship management around AI rather than adding AI to a conventional CRM.
In February 2026, the company announced a $20 million Series A led by Sequoia Capital alongside general availability of its platform.
The basic thesis is easy to understand.
Traditional CRM systems ask sales teams to enter and maintain large amounts of structured information. Day AI wants the system to understand conversations, activity, and customer data automatically, then answer business questions without requiring users to build endless reports.
Why Day AI Matters
CRM is one of the biggest enterprise software markets in the world, but it also carries a lot of administrative work.
That makes it a natural target for AI-native redesign.
The real disruption may not come from putting a chatbot inside a traditional CRM. It may come from reducing the amount of manual CRM work that users need to do in the first place.
What to Watch
Watch data quality.
An AI CRM becomes extremely useful if it quietly creates a reliable understanding of customers and deals. It becomes dangerous if people stop maintaining data manually while the automated system records the business incorrectly.
Accuracy will determine whether AI-native CRM becomes a system of record.
21. OpenHands
OpenHands is building open infrastructure for software-development agents.
The Boston company announced an $18.8 million Series A in November 2025, bringing total disclosed financing to about $23.8 million. Its approach is model-agnostic, allowing developers to use different AI models rather than being locked to one provider.
In May 2026, OpenHands introduced an agent control plane aimed at helping organizations manage coding agents across larger development environments.
Why OpenHands Matters
Coding agents are quickly moving from personal productivity tools into company infrastructure.
That changes the problem.
An enterprise may soon run hundreds or thousands of AI coding tasks. Managers will need permissions, monitoring, identity, cost controls, model choice, logs, testing, and ways to understand what every agent changed.
That creates a control-layer market.
What to Watch
Watch whether OpenHands becomes infrastructure rather than only a popular developer tool.
The companies that manage agent fleets could become strategically important even if the underlying AI models continue changing.
22. EnFi
EnFi brings AI agents into commercial lending.
The Boston company announced a $15 million Series A in February 2026, bringing total disclosed funding to $22.5 million. Reuters reported that the startup uses AI agents to analyze commercial credit applications and related lending information.
Commercial lending is a strong candidate for AI because it involves large amounts of documents, financial data, policy rules, analysis, and repeated review.
It is also a high-stakes field where mistakes can be expensive.
Why EnFi Matters
Financial institutions often have valuable data trapped inside documents and manual processes.
AI can reduce that burden, but banks cannot simply hand decisions to an opaque model.
The opportunity is therefore controlled automation: software that performs analysis and prepares decisions while preserving rules, evidence, review, and accountability.
What to Watch
Watch whether EnFi can make underwriters materially more productive without weakening credit quality.
That is the business case that matters.
If a lender can evaluate more opportunities with the same team while maintaining strong controls, AI becomes an operating advantage rather than a novelty.
23. Gradient AI
Gradient AI is one of the more established businesses on this list.
The Boston company builds AI for insurance, with products focused on areas such as underwriting, claims, and risk. Gradient announced a $56.1 million Series C in 2024, and in March 2026 it added growth capital from CIBC Innovation Banking.
The company says its technology has been deployed hundreds of times across insurance organizations.
Why Gradient Matters
Insurance is exactly the sort of market where Boston can build durable vertical AI.
The data is specialized. Regulations matter. Risk models matter. Historical workflows are complicated. Buyers care about measurable economic results.
That makes industry knowledge important.
What to Watch
Watch whether generative and agentic AI become connected to the predictive systems insurers already use.
The largest opportunity may not be a standalone insurance chatbot. It may be a system that connects underwriting models, documents, claims information, workflows, and human approvals into one decision process.
24. Rindler
Rindler is another very young Boston startup and a member of Y Combinator’s Summer 2026 group.
The company is building infrastructure intended to help AI agents interact more reliably with software and the web. Current company descriptions position Rindler around creating a translation layer between AI agents and online systems.
At this stage, Rindler is much earlier than companies such as 7AI or Gradient AI.
That means the reason to watch it is not current scale.
It is the problem it has chosen.
Why Rindler Matters
AI agents need dependable ways to act.
The open web was designed for humans using browsers, while APIs were generally designed for software developers. Autonomous agents sit awkwardly between those two worlds.
If millions of agents begin interacting with services, companies may need new infrastructure specifically designed for machine-to-machine actions.
What to Watch
Watch whether Rindler finds a repeatable layer that developers are willing to build around.
Infrastructure companies become powerful when many applications quietly depend on them.
Creative AI
25. Suno
Suno is the outlier in our Boston dataset, and that makes it one of the most interesting companies on the list.
Rather than focusing on science, healthcare, or enterprise software, Suno builds generative AI for music. In June 2026, the Cambridge company announced a Series D of more than $400 million at a $5.4 billion post-money valuation.
Suno released its v6 generation model in September 2026 and has also been building relationships with major participants in the music industry.
Why Suno Matters
Generative music tests some of the biggest questions facing consumer AI.
Can AI create a product people want repeatedly rather than try once? Can a generative platform develop its own network effects? How will rights, licensing, artists, labels, creators, and AI companies work together?
Those questions are much larger than Suno itself.
What to Watch
The next phase is not only about model quality.
Watch retention, paid usage, creator workflows, licensing structures, music-industry partnerships, and whether Suno grows into a creative platform rather than remaining primarily a generation tool.
Its business relationships with the established music industry may become just as important as improvements in the model.
What Our 25 Companies Tell Us About Boston’s AI Strategy
The individual companies are interesting, but the larger pattern may matter more.
Boston is not producing one kind of AI company.
It is building a stack that moves from basic science to physical infrastructure to industry software.
Boston’s Biggest Edge May Be Domain Knowledge
The easiest AI product to copy is often a thin application that sends a prompt to someone else’s model and puts a new interface around the answer.
Boston’s stronger startups tend to have another layer.
Videa understands dentistry. Gradient understands insurance. Beacon understands neurological signals. Dyno works with gene-delivery systems. Code Metal works with low-level mission-critical software. Tomorrow.io operates weather infrastructure. Reframe has to manufacture actual homes.
That domain depth creates friction for competitors.
A new competitor cannot reproduce years of clinical, scientific, regulatory, manufacturing, or engineering knowledge by writing a better prompt.
Chart 4: Where Boston AI Creates Its Defensibility
| AI Business Type | Main Defensive Advantage |
|---|---|
| Scientific AI | Proprietary experiments, models and scientific data |
| Healthcare AI | Clinical evidence, regulation and workflow integration |
| Physical AI | Hardware, manufacturing and deployment experience |
| Vertical enterprise AI | Industry data, workflow depth and distribution |
| AI infrastructure | Reliability, integration and developer adoption |
| Creative AI | User network, product experience, models and rights relationships |
This framework gives founders a useful lesson.
Do not ask only, “How can we add AI?”
Ask, “What do we know, own, measure, or operate that a generic AI model does not?”
That is often where a lasting company begins.
The Laboratory Could Become One of Boston’s Most Important AI Interfaces
For the first generation of generative AI companies, the main interface was a chat box.
Boston may help create another important interface: the automated laboratory.
Lila Sciences is the clearest example, but the pattern goes deeper. Somite uses AI around cell production. AI Proteins designs molecules. Asimov combines software with biological engineering. Dyno uses machine learning to search biological design spaces.
MIT is also continuing to push automation around biology. In July 2026, the MIT Media Lab announced a $1 million Massachusetts Life Sciences Center grant to establish a cloud laboratory where users could conduct real biological experiments through remote infrastructure.
The long-term implication is important.
AI systems are limited by the data they receive.
Connect the model to instruments, robotics, and laboratories, and the system can help create new data instead of only learning from historical information.
That could be a much larger change than better scientific search.
Physical AI Could Become Boston’s Second Major Wave
Walden, Blue Water Autonomy, Reframe, Code Metal, Tomorrow.io, PSI, and Dipole all point toward a wider trend.
AI is leaving the browser.
The MIT entrepreneurship pipeline shows the same direction. Its September 2026 Demo Day included teams working across robotics, manufacturing, biotechnology, aerospace, finance, cybersecurity, and other real-world markets, with AI appearing throughout those industries.
That matters because Boston already has the surrounding talent required to build physical systems.
A robotics founder can recruit mechanical engineers. A biotech founder can find laboratory talent. A defense startup can find people familiar with aerospace and government programs. An AI infrastructure company can recruit from computer science, electrical engineering, photonics, and semiconductor research.
That density is difficult to create from scratch.
Boston Companies Should Stop Measuring AI by How Much It Chats
Another pattern appears across the enterprise companies.
The useful unit of AI is moving from the answer to the completed task.
For Maven AGI, the question is whether a customer issue gets resolved.
For 7AI, it is whether a security investigation gets completed correctly.
For EnFi, it is whether commercial-credit work becomes faster and more reliable.
For OpenHands, the useful result is working software.
For Day AI, it is accurate understanding of customers and deals without endless CRM administration.
That changes how businesses should evaluate AI vendors.
A Better AI Vendor Scorecard for Boston Businesses
| Question | Weak Signal | Strong Signal |
|---|---|---|
| What does the AI produce? | Answers and summaries | Completed work |
| How is accuracy measured? | Demo examples | Production metrics |
| What data advantage exists? | Public model knowledge | Proprietary or customer-specific data |
| Can humans review decisions? | Informal checking | Designed approval points |
| Does it integrate with workflow? | Separate chatbot | Works inside operating systems |
| Is value measurable? | “Employees save time” | Cost, revenue, speed or quality KPI |
| What happens when AI fails? | User discovers mistake | Detection, escalation and audit trail |
This is especially important for Boston’s regulated industries.
Hospitals, insurers, banks, biotech companies, manufacturers, and defense organizations cannot evaluate AI only by asking whether a demonstration looks impressive.
They need operational evidence.
What Boston Founders Should Learn From the 25 Companies
The strongest pattern in our research is not “raise more money.”
It is pick a difficult problem where AI has a reason to exist.
Start With the Bottleneck, Not the Model
Tomorrow.io did not begin with “How can we use a foundation model?”
Weather decisions were already difficult.
Clairity did not invent breast cancer screening because AI became fashionable.
The clinical problem already existed.
Code Metal did not create the need to modernize low-level software.
AI is valuable because it attacks an expensive existing bottleneck.
Founders should use the same test.
Find a workflow where organizations already spend a lot of money, time, labor, or risk. Then determine whether AI can change the underlying economics.
Build Around Data That Gets Better
Many of Boston’s most interesting companies can create a learning loop.
A scientific experiment produces new experimental data.
A deployed robot creates physical-world data.
A security investigation produces information about threats.
A lending workflow produces credit outcomes.
A clinical product can generate evidence.
That loop matters because the startup gets stronger as the product is used.
A company that depends entirely on the same external model and public data as every competitor has a much harder time creating a lasting advantage.
Do Not Ignore the Human Approval Layer
AI does not need maximum autonomy in every workflow.
A better question is: where is autonomy economically useful, and where should a human still make the decision?
This is especially important in Boston because many local AI markets involve medicine, biology, insurance, finance, infrastructure, security, and defense.
The best system may automate 90% of preparation while preserving a clear human decision point for the final 10%.
That is still a huge productivity improvement.
What Boston Businesses Should Do Right Now
You do not need to become an AI company to benefit from this ecosystem.
But local businesses should become better AI buyers.
Choose One Workflow With a Real Business Number Attached
Do not begin with “We need an AI strategy.”
Begin with a measurable problem.
Perhaps insurance submissions take three hours. Security analysts review hundreds of low-value alerts. Sales representatives spend Friday afternoon updating CRM records. Engineers lose days translating old code. Support teams repeatedly answer the same operational questions.
Write down the baseline.
Then test whether AI changes it.
Run the Pilot Against Existing Performance
A pilot without a baseline teaches almost nothing.
Suppose an AI system reviews 5,000 documents.
That sounds impressive, but the number alone has no business meaning.
How long did the old process take? How many people were required? How many mistakes occurred? How much did it cost? Did the new system improve speed without lowering quality?
That is the comparison executives need.
Make the Vendor Prove the Hard Part
Every AI company can show the clean case.
Ask to see the messy one.
Give the vendor incomplete information, an unusual customer request, an old document, a contradictory dataset, or a situation where the software should refuse to act.
The failure behavior tells you more than the perfect demo.
Design Escalation Before Automation
Before giving an AI system permission to act, decide what it cannot do.
Define dollar limits, permission boundaries, high-risk categories, exception cases, and required human approvals.
Then log what happened.
This approach lets companies adopt AI without pretending the system is perfect.
What Investors Should Watch in Boston Through 2027
Funding will continue to create headlines, but the next set of signals should be more operational.
For AI software, watch retention, gross margin, expansion, completed tasks, and workflow depth.
For scientific AI, watch validated discoveries, experimental throughput, commercial partnerships, and whether AI-generated results survive laboratory testing.
For physical AI, watch deployment hours, hardware reliability, factory output, manufacturing costs, and repeat orders.
For healthcare, watch regulatory progress, clinical evidence, reimbursement, hospital adoption, and measurable effects on patient or provider workflows.
This distinction is important because the Boston AI market is becoming too diverse for one startup scorecard.
A $20 million enterprise software company and a $300 million robotics company should not be evaluated in the same way.
Why Boston Could Become More Important as AI Gets More Specialized
The first wave of generative AI favored companies that could move extremely quickly.
The next wave may place more value on difficult knowledge.
Healthcare AI needs healthcare knowledge.
Industrial AI needs engineering.
Drug AI needs biology.
Robotics needs mechanical systems.
Defense autonomy needs hardware and field testing.
Scientific AI needs laboratories.
Boston already has those communities.
That does not guarantee that local startups will win. Capital can move. Employees can move. Companies can relocate. Large technology companies can enter almost any attractive market.
But specialization changes the competitive equation.
When AI becomes deeply connected to the industry it serves, being close to experts, customers, research institutions, laboratories, and specialized workers becomes more useful.
Boston has a lot of that density packed into a surprisingly small geographic area.
The Bigger Story: Boston Is Turning AI Into Infrastructure
The most important takeaway from these 25 companies is not that Boston has a lot of AI startups.
Most large technology regions can now make that claim.
The more important point is the type of AI being built.
Lila wants AI to participate in scientific discovery.
Walden wants intelligence inside robots.
Blue Water is putting autonomy into ships.
Reframe is moving software and robotics into home production.
Tomorrow.io connects AI to a satellite-powered weather system.
Beacon applies machine learning to brain signals.
Clairity turns medical images into future-risk information.
Dyno searches for better gene-delivery vehicles.
Code Metal applies AI to critical embedded software.
7AI gives autonomous agents security investigations to perform.
These are not simply new interfaces for the same office tasks.
They are attempts to change how real industries operate.
That may ultimately be Boston’s strongest AI position.
Silicon Valley will continue to build many of the world’s largest models and consumer platforms. New York will remain especially strong where AI meets finance, enterprise software, advertising, media, and business workflows.
Boston does not need to copy either city.
Its opportunity is to become one of the places where artificial intelligence meets science, medicine, machines, engineering, and other systems where being almost correct is not good enough.
If the next decade of AI is defined not only by systems that can talk, but by systems that can discover, design, build, diagnose, investigate, manufacture, and operate, Boston may be extremely well positioned.
25 Boston AI Startups to Watch in 2026: At a Glance
| Company | Main Area | Latest Disclosed Round Used in Analysis |
|---|---|---|
| Lila Sciences | Autonomous science | $350M Series A |
| Physical Superintelligence | AI + physics | $58M seed |
| Osmo | Olfactory AI | $70M Series B |
| Axiomatic AI | Engineering and scientific AI | $18M seed |
| Walden Robotics | General-purpose robotics | $300M seed |
| Code Metal | AI software engineering | $125M Series B |
| Tomorrow.io | Weather intelligence | $210M Series F |
| Blue Water Autonomy | Autonomous ships | $50M Series A |
| Reframe Systems | Robotic construction | $40M equity financing |
| Dipole Labs | AI data-center infrastructure | Not publicly disclosed in our dataset |
| Beacon Biosignals | Brain data and AI | $97M+ Series B |
| Clairity | Cancer risk prediction | $43M Series B |
| Somite.ai | Cell engineering | $47M+ Series A |
| AI Proteins | Protein design | $41.5M Series A |
| Videa | Dental AI | $40M Series B |
| Asimov | Synthetic biology | $175M Series B |
| Dyno Therapeutics | AI gene therapy design | $100M Series A |
| 7AI | Cybersecurity agents | $130M Series A |
| Maven AGI | Customer-service AI | $50M Series B |
| Day AI | AI-native CRM | $20M Series A |
| OpenHands | Coding agents | $18.8M Series A |
| EnFi | Commercial lending AI | $15M Series A |
| Gradient AI | Insurance AI | $56.1M Series C |
| Rindler | Agent infrastructure | Not publicly disclosed in our dataset |
| Suno | Generative music | $400M+ Series D |
Frequently Asked Questions About Boston AI Startups
Is Boston a Major AI Startup Hub?
Yes, although Boston’s AI ecosystem has a different shape from Silicon Valley.
The region has major strengths in science, robotics, biotechnology, healthcare, engineering, cybersecurity, enterprise technology, and advanced computing. MIT says around 200 active Massachusetts-headquartered companies are based on MIT-licensed technologies alone, showing the depth of the research-to-company pipeline surrounding the region.
The Massachusetts government has also created an AI Hub intended to coordinate work across academia, industry, startups, and government.
Why Are So Many Boston AI Startups in Healthcare and Science?
Boston already has the people and institutions required to build those companies.
The area contains major hospitals, universities, biotechnology companies, medical researchers, laboratories, and engineering programs. AI therefore enters an ecosystem where founders can find both technical talent and people who deeply understand difficult scientific or medical problems.
That makes healthcare and scientific AI a natural local strength.
Which Boston AI Startup Has Raised the Largest Recent Round?
Among the 25 companies in our dataset, Suno has the largest most recent disclosed financing we identified, announcing more than $400 million in Series D funding in June 2026 at a $5.4 billion post-money valuation.
Lila Sciences follows with a $350 million Series A, while Walden Robotics launched with a $300 million seed round.
These numbers should not be interpreted as a ranking of company quality. Different industries require dramatically different amounts of capital.
What Is the Most Interesting Boston AI Trend in 2026?
The movement from digital-only AI toward scientific and physical AI is one of the clearest trends in our research.
Robots, laboratories, autonomous ships, biotechnology systems, weather satellites, factories, engineering tools, and medical systems appear repeatedly across the 25-company dataset.
That suggests Boston could play an important role in the next stage of AI, where intelligence becomes embedded in physical and scientific processes.
Are All 25 Companies Located Inside the City of Boston?
No.
We use “Boston AI startups” in the practical ecosystem sense and include Greater Boston companies in places such as Cambridge and Watertown, along with nearby Massachusetts technology centers tied directly into the region’s talent, capital, university, and customer networks.
Treating Cambridge as a separate startup ecosystem would make little practical sense when evaluating Boston technology. Founders, employees, investors, researchers, and customers routinely move across those municipal boundaries.
Final Takeaway
The Boston AI ecosystem in 2026 is becoming easier to understand once we stop asking whether the city can build the next generic chatbot.
That is probably the wrong question.
Boston’s deeper opportunity is building AI where the software needs to understand something difficult about the world: a cell, a molecule, a brain signal, a weather system, a house, a computer architecture, an insurance risk, a loan, a security incident, a robot, or a scientific experiment.
Our dataset supports that view.
Of the 25 companies selected, 40% operate primarily in scientific AI or physical/deep technology, while another 28% work in healthcare and life sciences. The 23 companies with comparable public financing figures represent at least $2.45 billion across their most recent disclosed rounds, and roughly 55% of that latest-round capital comes from financings announced in 2026.
The numbers are impressive.
The composition is more important.
Boston appears to be building an AI economy around problems where software alone is not enough. Success requires research, engineering, domain knowledge, physical infrastructure, clinical evidence, specialized data, or some combination of all six.
That is a difficult ecosystem to create.
Boston already has it.
